Slowing Cognitive & Functional Decline in Alzheimer’s Disease: Evaluating the Evidence–
The burden of AD is well known. In the United States, there are more than 5 million individuals with AD. This number is expected to climb to 7.7 million people by the year 2030. AD is now the sixth leading cause of death in the United States. As the US population ages, dementia syndromes such as AD are growing more prevalent. Roughly 60 to 80% of elderly patients with chronic dementia have AD, a progressive condition that leads to memory loss, personality changes, cognitive dysfunction, and functional impairment. The number of patients with AD continues to grow each year.
Senior care pharmacists play a critical role in ensuring that patients are evaluated, monitored, and treated appropriately. While current therapies cannot halt the disease, active medical management can significantly improve the quality of life for patients with AD and their caregivers and family members. As new evidence regarding optimal treatment approaches for AD continues to emerge, senior care pharmacists require education in order to continue providing care based on current best practices.
Implement strategies to support accurate and early identification of patients with Alzheimer’s disease.
Describe the need for the stage-specific management of patients with Alzheimer’s disease.
Outline the optimal use of pharmacologic and non-pharmacologic approaches in the management of Alzheimer’s disease.
Recommend medication regimens to minimize polypharmacy and medication adverse events in patients who have moderate to severe Alzheimer’s disease.
1.5 Free CPE for Pharmacists